Skip to content
Stop using now Drug recall · FDA · Published September 5, 2023

BE Pharmaceuticals Pantoprazole Sodium 40mg Vials Recall: Sterility Risk from Vial Cracks

BE Pharmaceuticals recalls Pantoprazole Sodium 40mg injection vials due to potential powder discoloration from cracks, risking contamination. Affected lots manufactured in India with specific expiration dates.

🇺🇸 FDA recall #D-1148-2023DrugBE Pharmaceuticals ›
Take action

Contact the company

Recalling firmBE PHARMACEUTICALS AGBundesstrasse 3 · Zug, Switzerland
✎ GovInfoNow plain-language explainer

BE Pharmaceuticals is recalling Pantoprazole Sodium 40mg injection vials that may have small cracks causing powder discoloration. This could lead to contamination and infection if used. Patients should not use these vials. Read more at govinfonow.com/recall/33136-be-pharmaceuticals-pantoprazole-sodium-40mg-vials-recall-sterility-risk-from.

Source Summary by GovInfoNow · govinfonow.com/recall/33136-be-pharmaceuticals-pantoprazole-sodium-40mg-vials-recall-sterility-risk-from · Updated August 17, 2026 · FDA enforcement record: FDA #D-1148-2023

Cite this page

“BE Pharmaceuticals Pantoprazole Sodium 40mg Vials Recall: Sterility Risk from Vial Cracks.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33136-be-pharmaceuticals-pantoprazole-sodium-40mg-vials-recall-sterility-risk-from. Based on FDA recall #D-1148-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1148-2023%22&limit=1).

The FDA announced on September 5, 2023, that BE Pharmaceuticals AG voluntarily recalled Pantoprazole Sodium for Injection due to a lack of sterility assurance caused by vial cracks. The recall affects 41,148 single-dose vials distributed nationwide in the USA.

How to tell if you have it

  • Brand: BE Pharmaceuticals
  • Product: Pantoprazole Sodium for Injection 40mg per vial
  • NDCs: 71839-122-01, 71839-122-10, 71839-122-25
  • Lot codes: GSC04002A, GSC04003A, GSC04004A, GSC04006A, GSC05001A, GSC05006A, GSC05007A, GSC10003A, GSC10005A, GSC06004A, GSC06005A, GSC07001A, GSC07007A, GSC07008A, GSC07009A, GSC08001A, GSC05009A, GSC04005A, GSC06003A, GSC10001A, GSC07006A, GSC08002A, GSD02012A, GSD03005A, GSD03008A

The hazard

The recall cites a lack of assurance of sterility because powder discoloration resulted from small cracks in some vials. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show BE Pharmaceuticals AG has one other recall on record since January 10, 2024, specifically for Fosaprepitant Injection due to sterility risk after reconstitution. Other recent recalls of similar products include Hetero Labs Pantoprazole Tablets Recall (March 26, 2026), Fresenius Kabi 1000mL Sodium Chloride Injection Recall (March 11, 2026), and OneSource Specialty Pharma Methohexital Sodium Recall (June 7, 2026).

How to tell if you have this one

Check for vials with NDC 71839-122-01 (10 single-dose) or NDC 71839-122-10 (25 single-dose). Look for specific lot numbers listed in the recall notice, such as GSC04002A through GSD03008A with expiration dates up to January 2025.

  • Brand
    BE Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Stop Using Vials Immediately

    Discard all recalled vials to prevent potential contamination and infection.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 19 months after the firm started it.

1. Firm started the recall: Sep 5, 202312. FDA classified it Class II: Sep 11, 202323. Published in FDA’s Enforcement Report: Sep 20, 202334. FDA terminated the recall: Apr 8, 2025420232025
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1148-2023 (September 5, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1148-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA